

## 1. Datos de Contacto:

**Nombre:** Juan Carlos Roa Strauch

**Cargo académico:** Jefe Departamento Anatomía Patológica

**Departamento o División:** Anatomía Patológica

**Nombre de su laboratorio :** Gallbladder Cancer Research Lab.

**Ubicación del Laboratorio:** Portugal 61/ Marcoleta 377

**Mail:** jcroa@med.puc.cl

**Anexos:** 3889- 1061

## 2. Líneas de Investigación:

1. Patología Quirúrgica de la Vesícula Biliar.
2. Búsqueda y validación de Blancos para Terapia Especifica dirigida en tumores digestivos (Colon, Estómago, Vesícula biliar).
3. Carcinogénesis de la Vesícula biliar. (Inflamación y cáncer de vesícula biliar)
4. Búsqueda y validación de biomarcadores ( proteómicos, miRNA genéticos) de diagnóstico, predisposición genética, pronóstico, predicción de respuesta a terapia de cáncer de vesícula biliar.
5. Exosomas como biomarcador en cáncer de vesícula biliar.
6. Validación de programa de biopsia líquida en Oncología.
7. Biobancos

## 3. Proyectos de Investigación:

1. **2009-2013** VALIDATION OF MTOR METABOLIC PATHWAY INACTIVATION FOR GALLBLADDER CANCER TARGETED THERAPY. Número **FONDECYT** 1090171. Investigador Responsable: ( CLP 200.000.000)
2. **2013-2015** PYROSEQUENCING PLATFORM FOR EPIGENETIC AND POLYMORPHISM RESEARCH. Investigador Responsable **FONDEQUIP** 120205. PI (CLP 93.000.000)
3. **2013-2017** IDENTIFICATION AND VALIDATION OF EARLY DIAGNOSTIC GALLBLADDER CANCER BIOMARKERS IN CHILEAN PATIENTS BY QUANTITATIVE PROTEOMICS. A PHASE 1 AND 2 BIOMARKER VALIDATION TRIAL." **Fondecyt Regular** 1130204. Investigador Responsable ( CLP 198.000.000)
4. **(2012-2014)** PLATAFORMA DE ESTUDIOS PRECLÍNICOS DE XENOTRANSPLANTES DE TEJIDOS METASTÁTICOS HUMANOS PARA LA EVALUACIÓN DE SENSIBILIDAD A DROGAS ANTICANCERÍGENAS. **FONDEF ideas** CA12i10333 (Director alterno) (CLP 180.000.000)

5. **2011-2014** CENTRO DE EXCELENCIA EN STUDIOS GENETICOS E INMUNOLÓGICOS (CEGIN) **Corfo Innova** Co Pi ( subdirector) (CLP 450.000.000)
6. **(2012- 2015)** IMPROVING THE PRODUCTION OF PHENYLPROPANOIDS WITH ANTIOXIDANT ACTIVITY IN HIGHBUSH BLUEBERRY (VACCINIUM CORYMBOSUM L.) USING METHYL JASMONATE AND UV-B RADIATION AND ITS EFFECT ON GASTRIC cancer chemoprevention. Co investigador **Fondecyt** 1120917 CoPI. (CLP 150.000.000)
7. **2012-2013** A PILOT STUDY OF GALLBLADDER CANCER IN CHILE **NCI- Chile**. Chilean Co-Pi. (USD 10.000)
8. **2012- 2015** PROYECTO BIOBANCO FACULTAD MEDICINA Hospital Sotero del Rio. Pontificia Universidad catolica de Chile. Director. **(PUC)**
9. **2013-2018** **Fondap**. Centro de Estudios Avanzados de Enfermedades Crónicas (**ACCDIS**). **Investigador asociado**.
- 10.- **2015-2023** Proyecto **NCI** Chile Biliary Longitudinal Study (Chile BiLS) intramural CHILE Coinvestigador Chile. Coordinador área de Patología.
- 11.- **2015 – 2020** Proyecto **NCI** RO1 “Lifetime arsenic exposure and low dose cancer risks in a unique area in Chile”. Coinvestigador CA Pulmon.
- 12.- **(2013-2018)** Identification of activated tyrosine kinase signaling pathways associated with drug-resistant phenotype of gallbladder cancer by SILAC-based quantitative phosphoproteomics. **Fondecyt Iniciacion** Patricia Garcia ( Patrocinante).
- 13.-. **( 2013-2016)** Identification and validation of prognostic biomarkers and potential therapeutic targets of the Hippo signaling pathway in gallbladder cancer patients. **Fondecyt Postdoctorado**. Carolina Bizama ( tutor)
- 14/ **(2013-2016)** Transcriptomic profiling of gallbladder cancer progression. **Fondecyt Postdoctorado** Jaime Espinoza ( Tutor)
- 15.- **(2015-2018)** Proteomic signature of gallbladder cancer secreted exosomes: a dynamic approach to delineate their potential role during malignant progression and their clinical relevance as novel reservoir of circulating biomarkers. **Fondecyt Regular** Coinvestigador.

#### 4. Publicaciones:

##### Año 2015 (23)

1. BENEFICIAL EFFECTS OF MINERALOCORTICOID RECEPTOR BLOCKADE IN EXPERIMENTAL NON-ALCOHOLIC STEATOHEPATITIS Pizarro M, Solís N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P, Arab JP, Padilla O, Roa JC, Moshage H, Wree A, Inzaugarat E, Feldstein AE, Fardella CE, Baudrand R, Riquelme A, Arrese M. *Liver Int.* 2015 Feb 2. [Epub ahead of print] PubMed PMID: 25646700. **ISI 4,85**
2. CALCIUM CALMODULIN DEPENDENT KINASE KINASE 2 - A POTENTIAL THERAPEUTIC TARGET FOR GASTRIC ADENOCARCINOMA Yashwanth Subbannayya<sup>1,2,3\*</sup>, Nazia Syed<sup>1,4\*</sup>, Remya Raja<sup>1\*</sup>, Arivusudar Marimuthu<sup>1</sup>, Nandini Sahasrabuddhe<sup>1,5</sup>, Sneha M. Pinto<sup>1,5</sup>, Srikanth Srinivas Manda<sup>1,6</sup>, Santosh Renuse<sup>1,7</sup>, Manju H. C.<sup>1,8</sup>, Mohammed Abdul Lateef Zameer<sup>8</sup>, Jyoti Sharma<sup>1,5</sup>, Kotteazeth Srikumar<sup>4</sup>, Juan Carlos Roa<sup>9</sup>, M. Vijaya Kumar<sup>10</sup>, K. V. Veerendra Kumar<sup>10</sup>, T. S. Keshava Prasad<sup>1,5,6,7</sup>, Girija Ramaswamy<sup>3</sup>, Rekha Vijay Kumar<sup>8</sup>, Akhilesh Pandey<sup>11-15</sup>, Harsha Gowda<sup>1§</sup>, Aditi Chatterjee<sup>1§</sup> *Cancer Biol Ther.* 2015 Feb;16(2):336-45. doi: 10.4161/15384047.2014.972264. **ISI 3,07**
3. MACROPHAGE MIGRATION INHIBITORY FACTOR - A THERAPEUTIC TARGET IN GALLBLADDER CÁNCER. Tejaswini Subbannayya Pamela Leal Rojas Mustafa A Barbhuiya Remya Raja Santosh Renuse Gajanan Sathe Sneha Maria Pinto Nazia Syed Vishalakshi Nanjappa Arun H Patil Patricia Garcia Nandini A Sahasrabuddhe Bipin Nair Rafael Guerrero-Preston Sanjay Navani Pramod K Tiwari Vani Santosh David Sidransky T S Keshava Prasad Harsha Gowda Juan Carlos Roa Akhilesh Pandey Aditi *Cancer Biol Ther.* 2015;16(2):336-45. **ISI 3,07**
4. PATHOLOGIC EVALUATION AND REPORTING OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS (IPMNs) OF THE PANCREAS AND OTHER TUMORAL INTRAEPITHELIAL NEOPLASMS OF PANCREATOBILIARY TRACT: RECOMMENDATIONS OF VERONA CONSENSUS MEETING Volkan Adsay<sup>1</sup>, Mari Mino-Kenudson<sup>2</sup>, Toru Furukawa<sup>3</sup>, Olca Basturk<sup>4</sup>, Giuseppe Zamboni<sup>5</sup>, Giovanni Marchegiani<sup>6</sup>, Claudio Bassi<sup>7</sup>, Roberto Salvia<sup>7</sup>, Giuseppe Malleo<sup>7</sup>, Salvatore Paiella<sup>7</sup>, Christopher L. Wolfgang<sup>8</sup>, Hanno Matthaei<sup>9</sup>, G. Johan Offerhaus<sup>10</sup>, Mustapha Adham<sup>11</sup>, Marco J. Bruno<sup>12</sup>, Michelle Reid<sup>1</sup>, Alyssa Krasinskas<sup>1</sup>, Günter Klöppel<sup>13</sup>, Nobuyuki Ohike<sup>14</sup>, Takuma Tajiri<sup>15</sup>, Kee-Taek Jang<sup>16</sup>, Juan Carlos Roa<sup>17</sup>, Peter Allen<sup>18</sup>, Carlos Fernández-del Castillo<sup>19</sup>, Jin-Young Jang<sup>20</sup>; David S. Klimstra<sup>4</sup>, Ralph H. Hruban<sup>21</sup> *Ann Surg.* 2015 Mar 13. [Epub ahead of print] PubMed **ISI 8,3**

5. GENOME-WIDE DNA METHYLATION ANALYSIS REVEALS ESTROGEN-MEDIATED EPIGENETIC REPRESSION OF METALLOTHIONEIN-1 GENE CLUSTER IN BREAST CANCER. Jadhav RR, Ye Z, Huang RL, Liu J, Hsu PY, Huang YW, Rangel LB, Lai HC, Roa JC, Kirma NB, Huang TH, Jin VX. Clin Epigenetics. 2015 Feb 24;7(1):13. doi: 10.1186/s13148-015-0045-9. eCollection 2015. PubMed PMID: 25763113; PubMed Central PMCID: PMC4355986. **ISI 4,54**
6. MOLECULAR CLASSIFICATION OF GASTRIC CANCER: TOWARDS A PATHWAY-DRIVEN TARGETED THERAPY Riquelme Ismael\*, Saavedra Kathleen1\*, Espinoza Jaime A2,3, Weber Helga1, García Patricia, Nervi Bruno, Garrido Marcelo, Corvalán Alejandro H, Roa Juan Carlos2,3,6 and Bizama Carolin Oncotarget in press 2105 **ISI .6,36 \***
7. TARGETING SPECIFIC MOLECULAR PATHWAYS HOLDS PROMISE FOR ADVANCED GALLBLADDER CANCER THERAPY. Bizama C, Garcia P, Espinoza Nervi B, Roa JC, Cancer Treat Rev. 2015 Mar;41(3):222-34 **ISI 7,6\***
8. ASSOCIATION OF AFLATOXIN WITH GALLBLADDER CANCER IN CHILE Nogueira L, Foerster C, Groopman J, Egner P, Koshiol J, Ferreccio C. Gallbladder Cancer Chile Working Group.. JAMA. 2015 May 26;313(20):2075-7. doi: 10.1001/jama.2015.4559. **ISI 35.3**
9. LOSS OF EXPRESSION OF REPRIMO, A P53-INDUCED CELL CYCLE ARREST GENE, CORRELATES WITH INVASIVE STAGE OF TUMOR PROGRESSION AND P73 EXPRESSION IN GASTRIC CANCER Saavedra K, Valbuena J, Olivares W, Marchant MJ, Rodríguez A, Torres-Estay V, Carrasco-Avino G, Guzmán L, Aguayo F, Roa JC, Corvalán AH.. PLoS One. 2015 May 8;10(5): **ISI 3,53\***
10. STAT3 REGULATES ERBB-2 EXPRESSION AND CO-OPTS ERBB-2 NUCLEAR FUNCTION TO INDUCE MIR-21 EXPRESSION, PDCD4 DOWNREGULATION AND BREAST CANCER METASTASIS. Patricia Elizalde, Leandro Venturutti, Lucia Romero, Alejandro Urtreger, María Chervo, Rosalía Cordo Russo, María Mercogliano, Gloria Inurrigarro, Matías Pereyra, Cecilia Proietti, Franco Izzo, María Díaz Flaqué, Victoria Sundblad, Juan Roa, Pablo Guzmán, Elisa Bal de Kier Joffé, Eduardo Charreau, and Roxana Schillaci **Oncogene in press ISI 8.46**
11. EXPRESSION OF INSULIN-LIKE GROWTH FACTOR I RECEPTOR AS A BIOMARKER FOR PREDICTING PROGNOSIS IN BILIARY TRACT CANCER PATIENTS. Suzuki H, Roa JC, Kawamoto T, Ishige K, Wistuba II, Li D, Thomas MB, Shoda J. Mol Clin Oncol. 2015 May;3(3):464-470. Epub 2015 Feb 25. PubMed PMID: 26137252; PubMed Central PMCID: PMC4471625. **NO ISI**

12. GALLBLADDER CANCER: EXPERT CONSENSUS STATEMENT. Aloia TA, Járufe N, Javle M, Maithel SK, Roa JC, Adsay V, Coimbra FJ, Jarnagin WR. *HPB (Oxford)*. 2015 Aug;17(8):681-690. doi: 10.1111/hpb.12444. PubMed PMID: 26172135. **ISI 2,68\***
13. [GENOTYPING OF HUMAN PAPILLOMAVIRUS IN WOMEN UNDER 25 YEARS OLD TREATED IN THE SCREENING PROGRAM FOR CERVICAL CANCER]. Melo A, Vásquez AM, Andana A, Matamala M, Pino T, Guzmán P, Hoffstetter R, Ili C, Brebi P, Roa JC *Rev Chilena Infectol*. 2014 Oct;31(5):542-8. doi: 10.4067/S0716-10182014000500005. Spanish. PubMed PMID: 25491452. **ISI 0,494\***
14. -TUMOR LOCATION IS A STRONG PREDICTOR OF TUMOR PROGRESSION AND SURVIVAL IN T2 GALLBLADDER CANCER: AN INTERNATIONAL MULTICENTER STUDY IN PRESS *ANNALS OF SURGERY*. [Shindoh J<sup>1</sup>](#), [de Aretxabala X](#), [Aloia TA](#), Roa JC, [Roa I](#), [Zimmitti G](#), [Javle M](#), [Conrad C](#), [Maru DM](#), [Aoki T](#), [Vigano L](#), [Ribero D](#), [Kokudo N](#), [Capussotti L](#), [Vauthey JN](#). *Ann Surg*. 2015 Apr;261(4):733-9. doi: 10.1097/SLA.0000000000000728. **ISI 8,3**
15. GLOBAL PHOSPHOTYROSINE SURVEY IN TRIPLE-NEGATIVE BREAST CANCER REVEALS ACTIVATION OF MULTIPLE TYROSINE KINASE SIGNALING PATHWAYS Xinyan Wu<sup>1,2#</sup>, Muhammad Saddiq Zahari<sup>1,2#</sup>, Binyun Ma<sup>6</sup>, Ren Liu<sup>6</sup>, Santosh Renuse<sup>1,2,5</sup>, Nandini A Sahasrabudhe<sup>1,2,5</sup>, Lily Chen<sup>3</sup>, Raghothama Chaerkady<sup>1,2</sup>, Min-Sik Kim<sup>1,2</sup>, Jun Zhong<sup>1,2</sup>, Christine Jelinek<sup>1,2</sup>, Mustafa A. Bharbuiya<sup>1,2,5</sup>, Pamela Leal-Rojas<sup>1,2,7</sup>, Yi Yang<sup>1,2</sup>, Manoj Kumar Kashyap<sup>1,2,5</sup>, Arivusudar Marimuthu<sup>1,2,5</sup>, Min Ling<sup>1</sup>, Mary Jo Fackler<sup>3</sup>, Vanessa Merino<sup>3</sup>, Zhen Zhang<sup>3</sup>, Cynthia A Zahnow<sup>3</sup>, Edward Gabrielson<sup>3,4</sup>, Vered Stearns<sup>3</sup>, Juan Carlos Roa<sup>7</sup>, Saraswati Sukumar<sup>3</sup>, Parkash S Gill<sup>6</sup> and Akhilesh Pandey<sup>1,2,3,4\*</sup> *Oncotarget* submitted **ISI 6,4**
16. QUANTITATIVE PHOSPHOPROTEOMIC ANALYSIS OF IL-33-MEDIATED SIGNALING Pinto SM, Nirujogi RS, Rojas PL, Patil AH, Manda SS, Subbannayya Y, Roa JC, Chatterjee A, Prasad TS, Pandey A. *Proteomics*. 2015 Jan;15(2-3):532-44. doi: 10.1002/pmic.201400303. PubMed PMID: 25367039. **ISI 3,973**
17. TARGETING ERBB-2 NUCLEAR LOCALIZATION AND FUNCTION INHIBITS BREAST CANCER GROWTH AND OVERCOMES TRASTUZUMAB RESISTANCE Cordo Russo RI, Béguelin W, Díaz Flaqué MC, Proietti CJ, Venturutti L, Galigniana N, Tkach M, Guzmán P, Roa JC, O'Brien NA, Charreau EH, Schillaci R, **Elizalde PV**. *Oncogene*. 2014 Sep 1;0. doi: 10.1038/onc.2014.272. [ **ISI 8,55**
18. EFFECTS OF c-FLIPL KNOCKDOWN IN CERVICAL UTERINE CARCINOMA CELL LINES Carmen G. Ili<sup>1</sup>, Priscilla Brebi<sup>1</sup>, Patricia Garcia<sup>1,2</sup>, Pamela Leal<sup>1</sup>, Jaime Lopez<sup>1</sup>, Oscar Tapia<sup>1</sup>, Pablo Letelier<sup>1</sup>,

Helga Weber<sup>1</sup>, Juan C. Roa<sup>1,2\*</sup>. In press a International Journal of Morphology In Press **ISI 0,3\***

19. "HEREGULIN CO-OPTS PR TRANSCRIPTIONAL ACTION VIA STAT3 ROLE AS A COREGULATOR TO DRIVE CANCER GROWTH", Proeitti C Roa JC, Elizalde P In press Molecular Endocrinology **ISI 4.022\***
20. LOW EXPRESSION OF ENT1 IS ASSOCIATED WITH POOR PROGNOSIS IN CHEMOTHERAPY-NAÏVE PT2 GALLBLADDER ADENOCARCINOMA PATIENTS Espinoza J , Garcia P, Nervi B , Roa JC **Plos One ISI 3,5\***
21. "RAPAMYCIN AND WYE-354 SUPPRESS HUMAN GALLBLADDER CANCER XENOGRAFTS IN MICE" Riquelme Ismael,\* , Saavedra Kathleen<sup>1\*</sup>, Espinoza Jaime A<sup>2,3</sup>, Weber Helga<sup>1</sup>, García Patricia, Nervi Bruno, Garrido Marcelo, Corvalán Alejandro H, Roa Juan Carlos<sup>2,3,6</sup> and Bizama Carolin Oncotarget in press 2015 **ISI .6,36\***
22. MIR-101-2, MIR-125B-2 AND MIR-451A ACT AS POTENTIAL TUMOR SUPPRESSORS IN GASTRIC CANCER AND AGS CELLS THROUGH THE REGULATION IN THE PI3K/AKT/MTOR PATHWAY. Ismael Riquelme<sup>1\*</sup>, Oscar Tapia<sup>1\*</sup>, Pamela Leal<sup>2</sup>, Alejandra Sandoval<sup>1</sup>, Matthew G. Varga<sup>3</sup>, Pablo Letelier<sup>4</sup>, Kurt Buchegger<sup>1</sup>, Carolina Bizama<sup>5</sup>, Jaime A. Espinoza<sup>5</sup>, Richard M. Peek<sup>3</sup>, Juan Carlos Roa<sup>5ψ</sup> **Cellular Oncology In press 3.032 July 2015. \***
23. THE ACTIVATED STATUS OF THE PI3K/AKT/MTOR PATHWAY IN TUMORAL TISSUES AND THREE CELL LINES OF GASTRIC CANCER. Ismael Riquelme<sup>1\*</sup>, Oscar Tapia<sup>1\*</sup>, Jaime A. Espinoza<sup>2</sup>, Pamela Leal<sup>3</sup>, Alejandra Sandoval<sup>1</sup>, Kurt Buchegger<sup>1</sup>, Carolina Bizama<sup>2</sup>, Patricia García<sup>2</sup>, Juan Carlos Araya<sup>1</sup>, Juan Carlos Roa<sup>2,4</sup> **International Journal of sciences submmited July 2015 ISI 2,17**

### **Año 2014 (13)**

1.- IMMUNOHISTOCHEMICAL ANALYSIS OF THE PI3K/AKT/mTOR PATHWAY IN GASTRIC CANCER: CORRELATION WITH CLINICOPATHOLOGICAL FEATURES AND CUMULATIVE SURVIVAL. Tapia O, Riquelme I, Leal P, Sandoval A, Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P, Roa JC. Virchows Arch. 2014 May 21. [Epub ahead of print] PubMed PMID: 24844205. DOI 10.1007/s00428-014-1588-4 **ISI 2,676**

2.-"HYPERMETHYLATION OF TUMOR SUPPRESSOR GENE P53 IN CHILEAN PATIENTS UNDER 15 YEARS WITH ACUTE LYMPHOBLASTIC LEUKEMIA."

Melo A<sup>1</sup>, Artigas CG<sup>2</sup>, Fritz C<sup>1</sup>, Díaz P<sup>1</sup>, Muñoz S<sup>3</sup>, Brebi P<sup>1</sup>, Roa JC<sup>1-4</sup>.

Int. J. Morphol., 32(4):1243-1247, 2014. <http://dx.doi.org/10.4067/S0717-95022014000400019>

**ISI 0.2**

3.-[GENOTYPING OF HUMAN PAPILLOMAVIRUS IN WOMEN UNDER 25 YEARS OLD TREATED IN THE SCREENING PROGRAM FOR CERVICAL CANCER]. Melo A, Vásquez AM, Andana A, Matamala M, Pino T, Guzmán P, Hoffstetter R, Ili C, Brebi P, Roa JC. Rev Chilena Infectol. 2014 Oct;31(5):542-8. doi: 10.4067/S0716-10182014000500005 (**ISI 0,494**)

4.-MIR-1 AND MIR-145 ACT AS TUMOR SUPPRESSOR MICRORNAS IN GALLBLADDER CANCER Pablo Letelier<sup>1,2</sup>, Patricia García<sup>3</sup>, Pamela Leal<sup>1</sup>, Héctor Álvarez<sup>4</sup>, Carmen Ili<sup>1</sup>, Jaime López<sup>1</sup> and Juan Carlos Roa<sup>1,3</sup>  
Int J Clin Exp Pathol. 2014 Apr 15;7(5):1849-67. eCollection 2014 **ISI 2,04**

5.-IDENTIFICATION OF PROSAPOSIN AND TRANSGELIN AS POTENTIAL BIOMARKERS FOR GALLBLADDER CANCER USING QUANTITATIVE PROTEOMICS CORRESPONDING AUTHOR: Sahasrabuddhe NA, Barbhuiya MA, Bhunia S, Subbannayya T, Gowda H, Advani J, Shrivastav BR, Navani S, Leal P, **Roa** JC, Chaerkady R, Gupta S, Chatterjee A, **Pandey** A, Tiwari PK. Biochem Biophys Res Commun. 2014 Apr 18;446(4):863-9. doi: 10.1016/j.bbrc.2014.03.017. Epub 2014 Mar 20. **ISI 2,4**

6.- "EVALUATION OF ZAR1 AND SFRP4 METHYLATION STATUS AS POTENTIAL BIOMARKERS FOR DIAGNOSIS AND PROGRESSION IN CERVICAL CARCINOGENESIS: EXPLORATORY STUDY PHASE I", Brebi P, Hoffstetter R, Andana A, Ili CG, Saavedra K, Viscarra T, Retamal J, Sanchez R, Roa JC Biomarkers. 2014 May;19(3):181-8 DOI: 10.3109/1354750X.2013.867535 **ISI 1.87**

7.-GENOME-WIDE METHYLATION PROFILING REVEALS ZINC FINGER PROTEIN 516 (*ZNF516*) AND FK-506-BINDING PROTEIN 6 (*FKBP6*) PROMOTERS FREQUENTLY METHYLATED IN CERVICAL NEOPLASIA, ASSOCIATED WITH HPV STATUS AND ETHNICITY IN A CHILEAN POPULATION Brebi P, Maldonado L, Noordhuis MG, Ili C, Leal P, Garcia P, Brait M, Ribas J, Michailidi C, Perez J, Ethan Soudry, Oscar Tapia, Pablo Guzman, Sergio Muñoz, Leander Van Neste, Wim Van Criekinge, Rafael Irizarry, David Sidransky, Juan C Roa\*, Rafael Guerrero-Preston \*Epigenetics 2014; 9:0 - -1; PMID: 24241165; <http://dx.doi.org/10.4161/epi.27120> **ISI 4.9**

8.- IMMUNOHISTOCHEMICAL EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH FACTOR A IN ADVANCED GALLBLADDER CARCINOMA 1: Letelier P, Garcia P, Leal P, Ili C, Buchegger K, Riquelme I, Sandoval A, Tapia O, Roa JC. Appl Immunohistochem Mol Morphol. 2014 Aug;22(7):530-6. doi: 10.1097/PAI.0b013e3182a318a9. **ISI 2.012.**

9: SYNCHRONOUS ILEOCECAL AND DUODENAL TUBERCULOSIS: CASE REPORT AND REVIEW OF THE LITERATURE. Villalon C, Quezada F, Hartmann J, Roa JC, Urrejola G. *Int J Colorectal Dis.* 2014 Aug;29(8):1027-8. doi: 10.1007/s00384-014-1894-y. Epub 2014 May 10. DOI 10.1007/s00384-014-1894-y **ISI 2,415**

10: COMPLETE PATHOLOGICAL RESPONSE TO IMATINIB MESYLATE IN AN EXTRAINTESTINAL GASTROINTESTINAL STROMAL TUMOR Quezada N, Acevedo F, Marambio A, León F, Galindo H, Roa JC, Jarufe N. *Int J Surg Case Rep.* 2014 Aug 5;5(10):681-685. doi: 10.1016/j.ijscr.2014.05.009. **NO ISI**

11.-INTRACHOLECYSTIC PAPILLARY TUBULAR NEOPLASM OF THE GALLBLADDER WITH MICROINVASIVE CARCINOMA. S Balci, G Akkas, JC Roa, NV Adsay *Pathology Case Reviews* 19 (6), 283-288. (**NO ISI**)

12.-EPIDEMIOLOGÍA DEL CÁNCER DE TIROIDES EN CHILE: RESULTADOS DEL ESTUDIO INCATIRJ Sapunar, S Muñoz, JC Roa *Revista médica de Chile* 2014 Sep;142(9):1099-105. doi: 10.4067/S0034-98872014000900002. **ISI (0,304)**

13.-HUMAN PAPILLOMA VIRUS FREQUENCY IN NON-GYNECOLOGICAL TUMORS IN THE ARAUCANÍA René Hoffstetter\* ; Alejandra Andana\* ; Pablo Guzmán\* ; Carmen G. Ili\* ; Javier Retamal\* ; Bárbara Mora\* ; Juan C. Roa\*\*\* & Raúl Sánchez\*\* Region, Chile *Int. J. Morphol.*, 32(4):1254-1260, 2014. <http://dx.doi.org/10.4067/S0717-95022014000400021>  
**(ISI 0.318)**

#### **Año 2013. (18)**

1.- CMS: A WEB-BASED SYSTEM FOR VISUALIZATION AND ANALYSIS OF GENOME-WIDE METHYLATION DATA OF HUMAN CANCERS. Gu F, Doderer MS, Huang YW, Roa JC, Goodfellow PJ, Kizer EL, Huang TH, Chen Y. *PLoS One.* 2013 Apr 22;8(4): **ISI 3,73**

2.-INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF/CCN2) IN GALLBLADDER CANCER CELLS LEADS TO DECREASED GROWTH IN VITRO. Garcia P, Leal P, Ili C, Brebi P, Alvarez H, Roa JC. *Int J Exp Pathol.* 2013 Jun;94(3):195-202 **ISI 2,6**

3.-TREATMENT OF THE RESIDUAL CAVITY DURING HEPATIC HYDATIDOSIS SURGERY: A COHORT STUDY OF CAPITONNAGE VS. OMENTOPLASTY. Manterola C, Roa JC, Urrutia S; MINCIR Group. *Surg Today.* 2013 Apr 6. [Epub ahead of print] **ISI 1,22**

4.-IMMUNOHISTOCHEMICAL EXPRESSION OF PHOSPHO-MTOR IS ASSOCIATED WITH POOR PROGNOSIS IN PATIENTS WITH



GALLBLADDER ADENOCARCINOMA. Leal P, García P, Sandoval A, Letelier P, Brebi P, Ili C, Alvarez H, Tapia O, Roa JC. Arch Pathol Lab Med. 2013 Apr;137(4):552-7. **ISI,2,5**

5.-CELLULAR FLICE-LIKE INHIBITORY PROTEIN LONG FORM (C-FLIPL) OVEREXPRESSION IS RELATED TO CERVICAL CANCER PROGRESSION.

Ili CG, Brebi P, Tapia O, Sandoval A, Lopez J, Garcia P, Leal P, Sidransky D, Guerrero-Preston R, Roa JC. Int J Gynecol Pathol. 2013 May;32(3):316-22 **ISI 1,413**

6.-NEOADJUVANT CHEMORADIATION THERAPY FOR BORDERLINE PANCREATIC ADENOCARCINOMA: REPORT OF TWO CASES.

Galindo J, Gabrielli M, Guerra JF, Cassina JC, Garrido M, Jarufe N, Borghero Y, Madrid J, Zoroquiain P, Roa JC, Martínez J. World J Surg Oncol. 2013 Feb 5;11:37. **ISI 1,12**

7.-CONNECTIVE TISSUE GROWTH FACTOR IMMUNOHISTOCHEMICAL EXPRESSION IS ASSOCIATED WITH GALLBLADDER CANCER PROGRESSION.

Garcia P, Leal P, Alvarez H, Brebi P, Ili C, Tapia O, Roa JC. Arch Pathol Lab Med. 2013 Feb;137(2):245-50. **ISI 2,3**

8.-ROKITANSKY ASCHOFF SINUSES INVOLMENT IN EARLY GALLBLADDER CARCINOMA AS A PROGNOSTIC FACTOR. A CONCURRENT COHORT STUDY Roa JC, Tapia O, Manterola C, Villaseca M, Guzman P, Araya JC, Bagci P, Saka

B, Adsay V. Early gallbladder carcinoma has a favorable outcome but Rokitansky-Aschoff sinus involvement is an adverse prognostic factor Virchows Arch. 2013 Nov;463(5):651-61. **ISI 2,676**

9.- [FREQUENCY OF CHLAMYDIA TRACHOMATIS INFECTION IN A GROUP OF WOMEN FROM REGION OF ARAUCANÍA, CHILE]. Silva R, León D, Viscarra T, Ili C, Roa JC, Sánchez R, Guzmán P, Brebi P Rev Chilena Infectol. 2013 Dec;30(6):611-5. **ISI 0,497**

10.-

[CRITERIA FOR PATHOLOGIC SAMPLING OF GALLBLADDER SPECIMEN S.](#)

Adsay V, Saka B, Basturk O, Roa JC, Renshaw A, Gould E. Am J Clin Pathol. 2013 Aug;140(2):278-80. **ISI 2,6**

11.- EXOME SEQUENCING REVEALS FREQUENT INACTIVATING MUTATIONS IN CHROMATIN REMODELING GENES IN INTRAHEPATIC CHOLANGIOCARCINOMAS BUT NOT IN GALLBLADDER CARCINOMAS

Yuchen Jiao\*, Timothy M. Pawlik\*, Robert A. Anders\*, Florin Selaru, Mirte M. Streppel, Anirban Maitra, Pedram Argani, G. Johan A. Offerhaus, Juan Carlos Roa, Victor E. Velculescu, Ralph H. Hruban, Bert Vogelstein, Kenneth W. Kinzler+, Nickolas Papadopoulos+, and Laura D. Wood Nat Genet. 2013 Nov 3. doi: 10.1038/ng.2813. **ISI 35,2.**

**12.- AKT/MTOR SUBSTRATE P70S6K IS FREQUENTLY PHOSPHORYLATED IN GALLBLADDER CANCER TISSUE AND CELL LINES.**

Leal P, Garcia P, Sandoval A, Buchegger K, Weber H, Tapia O, Roa JC *Onco Targets Ther.* 2013 Oct 3;6:1373-84 **ISI 2.07**

**13.- VIRULENCE OF INFECTING *HELICOBACTER PYLORI* STRAINS AND AMOUNT OF MONONUCLEAR CELL INFILTRATION ARE ASSOCIATED WITH LEVELS OF DNA HYPERMETHYLATION IN GASTRIC MUCOSAE**

**Schneider** BG, Piazuolo MB, Sicinski LA, Mera R, Peng DF, **Roa** JC, Romero-Gallo J, Delgado AG, de Sablet T, Bravo LE, Wilson KT, El-Rifai W, Peek RM Jr, Correa P. *Epigenetics.* 2013 Nov;8(11):1153-61. **ISI 4,5.**

14.- SILAC-BASED QUANTITATIVE PROTEOMIC ANALYSIS OF GASTRIC CANCER SECRETOME. Marimuthu A, Subbannayya Y, Sahasrabudhe NA, Balakrishnan L, Syed N, Sekhar NR, Katte TV, Pinto SM, Srikanth SM, Kumar P, Pawar H, Kashyap MK, Maharudraiah J, Ashktorab H, Smoot DT, Ramaswamy G, Kumar RV, Cheng Y, Meltzer SJ, Roa JC, Chaerkady R, Prasad TS, Harsha HC, Chatterjee A, Pandey A. *Proteomics Clin Appl.* 2013 Jun;7(5-6):355-66. **ISI 2,925.**

15.-“PROGESTERONE RECEPTOR ASSEMBLY OF A TRANSCRIPTIONAL COMPLEX ALONG WITH AP-1, STAT3 AND ERBB-2 GOVERNS BREAST CANCER GROWTH AND PREDICTS RESPONSE TO ENDOCRINE THERAPY”, Díaz Flaqué MC, Galigniana NM, Béguelin W, Vicario R, Proietti CJ, Russo RC, Rivas MA, Tkach M, Guzmán P, Roa JC, Maronna E, Pineda V, Muñoz S, Mercogliano MF, Charreau EH, Yankilevich P, Schillaci R, Elizalde PV *Breast Cancer Res.* 2013 Dec 17;15(6):R118. [Epub ahead of print] PubMed PMID **BCR (ISI 5.87)**

16.- PERFIL DE METILACIÓN DE GENES SUPRESORES DE TUMORES APAF1, ASSP1, P73 Y FHIT EN PACIENTES CON LEUCEMIA

LINFOBLÁSTICA AGUDA INFANTIL ANGÉLICA Melo, Carmen Gloria Artigas, Sergio Muñoz, Priscilla Brebi, Rene Hoffstetter, Juan Carlos Roa *Int Journal Of Morphology* 31 (3) : 973-79 **ISI 0,213**

17.- HUMAN PAPILLOMAVIRUS INFECTION IN MEN AND ITS RELATION WITH CANCER: CURRENT STATUS AND PROSPECTICS. Priscilla Brebi

M. <sup>a, b</sup>, Ricardo Hartley B. <sup>a</sup>, Carmen G. Ili <sup>a, b</sup>, [Juan Carlos Roa S. <sup>b, c</sup>](#), Raúl Sánchez G. <sup>a</sup>. *Revista Internacional de Andrologia* 11 (1) 2013 :25-30. **ISI 0.220**

18: [DETECTION OF HUMAN PAPILLOMA VIRUS INFECTION IN MEN] Silva R, León D, Brebi P, Ili C, Roa JC, Sánchez R. . *Rev Chilena Infectol.* 2013 Apr;30(2):186-92. doi: 10.4067/S0716-10182013000200009. Review. Spanish. PubMed PMID: 23677157. **ISI 0,497**

**Año 2012**

1. .- *CLINICAL AND PUBLIC HEALTH RESEARCH USING METHYLATED DNA IMMUNOPRECIPITATION (MEDIP): A COMPARISON OF COMMERCIALY AVAILABLE KITS TO EXAMINE DIFFERENTIAL DNA METHYLATION ACROSS THE GENOME.* [Brebi-Mieville P](#), [Ili-Gangas C](#), [Leal-Rojas P](#), [Noordhuis MG](#), [Soudry E](#), [Perez J](#), [Roa JC](#), [Sidransky D](#), [Guerrero-Preston R](#). 1.- Epigenetics. 2012 Jan 1;7(1).. **ISI 4,6**
2. 2.4CLINICAL RELEVANCE OF ERBB-2/HER2 NUCLEAR EXPRESSION IN BREAST CANCER. Roxana Schillaci<sup>1</sup>, Pablo Guzmán González<sup>2</sup>, Florencia Cayrol<sup>1</sup>, Wendy Beguelin<sup>1</sup>, María C. Díaz Flaqué<sup>1</sup>, Cecilia J. Proietti<sup>1</sup>, Juan C. Roa Strauch<sup>2</sup>, Viviana Pineda Nesbet<sup>3</sup>, Jorge Palazzi<sup>4</sup>, Isabel Frahm<sup>5</sup>, Eduardo H. Charreau<sup>1</sup>, Patricia V. Elizalde<sup>1</sup> BMC 2012 Feb 22;12:74. **ISI 3,1**
3. GENE EXPRESSION PROFILING OF GASTRIC CANCER : Marimuthu A, Jacob HKC, Jakharia A, Subbannayya Y, Keerthikumar S, et al. (2011) Gene Expression Profiling of Gastric Cancer. J Proteomics Bioinform 2012 4: 074-082. doi:10.4172/jpb.1000170 **NO ISI**
4. OVEREXPRESSION OF RIBOSOME BINDING PROTEIN 1 (RRBP1) IN BREAST CANCER. Telikicherla D, Marimuthu A, Kashyap MK, Ramachandra YL, Mohan S, Roa JC, Maharudraiah J, Pandey A. Clin Proteomics. 2012 Jun 18;9(1):7. doi: 10.1186/1559-0275-9-7. **NO ISI**
- 5.- OVEREXPRESSION OF KINESIN ASSOCIATED PROTEIN 3 (KIFAP3) IN BREAST CANCER. Deepthi T, Jagadeesha M, Harsh P, Arivusudar M, Manoj Kumar K, et al. (2012) . J Proteomics Bioinform 5: 122-126. doi:10.4172/jpb.1000223 **No ISI**
- 6.- EPIGENETIC ALTERATIONS IN PRENEOPLASTIC AND NEOPLASTIC LESIONS OF UTERINE CERVIX Kathleen Saavedra P.1, a, b, Priscilla Brebi M 1, a and Juan Carlos Roa S1, 2. Clin Epigenetics. 2012 Aug 31;4(1):13. **ISI6,22**
- 7.- DNA PROMOTER METHYLATION AS A DIAGNOSTIC AND THERAPEUTIC BIOMARKER IN GALLBLADDER CANCER Letelier P, Brebi P, Tapia O, Roa JC.. Clin Epigenetics. 2012 Jul 13;4(1):11. **ISI 6,22**
- 8.- INTRACHOLECYSTIC PAPILLARY-TUBULAR NEOPLASMS (ICPN) OF THE GALLBLADDER (NEOPLASTIC POLYPS, ADENOMAS, AND PAPILLARY NEOPLASMS THAT ARE ≥1.0 CM):CLINICOPATHOLOGIC AND IMMUNOHISTOCHEMICAL ANALYSIS OF 123 CASES. Adsay V, Jang KT, Roa JC, Dursun N, Ohike N, Bagci P, Basturk O, Bandyopadhyay S, Cheng JD, Sarmiento JM, Escalona OT, Goodman M, Kong SY, Terry P. Am J Surg Pathol. 2012 Sep;36(9):1279-301. **ISI 4,4**
- 9.- "MUCINOUS CARCINOMAS OF THE GALLBLADDER: CLINICOPATHOLOGIC ANALYSIS OF 15 CASES IDENTIFIED IN 606

CARCINOMAS" Dursun N, Escalona OT, Roa JC, Basturk O, Bagci P, Cakir A, Cheng J, Sarmiento J, Losada H, Kong SY, Ducato L, Goodman M, Adsay NV. Arch Pathol Lab Med. 2012 Nov;136(11):1347-58 **ISI 2.3**

10.- PATHOLOGIC STAGING OF PANCREATIC, AMPULLARY, BILIARY, AND GALLBLADDER CANCERS: PITFALLS AND PRACTICAL LIMITATIONS OF THE CURRENT AJCC/UICC TNM STAGING SYSTEM AND OPPORTUNITIES FOR IMPROVEMENT Adsay NV, Bagci P, Tajiri T, Oliva I, Ohike N, Balci S, Gonzalez RS, Basturk O, Jang KT, Roa JC. Semin Diagn Pathol. 2012 Aug;29(3):127-41. **ISI 1.612**

### **Año 2011 (12)**

1. HPV GENOTYPING FROM CERVICAL INTRAEPITHELIAL NEOPLASIA IN CHILE. Carmen G. Ili<sup>a</sup>, Priscilla Brebi<sup>a</sup>, Jaime López<sup>a</sup>, Patricia García<sup>a</sup>, Pamela Leal<sup>a</sup>, Eugenio Suarez<sup>b</sup>, Juan C. Roa<sup>a\*</sup>. J Med Virol. 2011 May;83(5):833-7. doi: 10.1002/jmv.22057. Epub 2011 Feb 25. **ISI 2.9**
2. SQUAMOUS CELL AND ADENOSQUAMOUS CARCINOMAS OF THE GALLBLADDER: CLINICOPATHOLOGICAL ANALYSIS OF 34 CASES JC Roa<sup>1</sup>O, Tapia<sup>1</sup>, A Cakir<sup>2</sup>, I Coban<sup>2</sup>, N Dursun<sup>2</sup>, O Basturk<sup>3</sup>, H. Losada<sup>1</sup>, J Sarmiento<sup>2</sup> and NV Adsay<sup>2</sup>. Mod Pathol. 2011 Aug;24(8):1069-78. **ISI 4.2**
3. WIDESPREAD HYPOMETHYLATION OCCURS EARLY AND SYNERGIZES WITH GENE AMPLIFICATION DURING ESOPHAGEAL CARCINOGENESIS. Hector Alvarez<sup>1</sup>, Joanna Opalinska<sup>5\*</sup>, Li Zhou<sup>5\*</sup>, Davendra Sohal<sup>5</sup>, Melissa J. Fazzari<sup>6</sup>, Yiting Yu<sup>5</sup>, Christina Montagna<sup>5</sup>, Elizabeth A. Montgomery<sup>1</sup>, Marcia Canto<sup>2</sup>, Kerry B. Dunbar<sup>2</sup>, Jean Wang<sup>2</sup>, Juan Carlos Roa<sup>10</sup> Yongkai Mo<sup>5</sup>, Tushar Bhagat<sup>5</sup>, K.H. Ramesh<sup>7</sup>, Linda Cannizzaro<sup>5</sup>, Jan Mollenhauer<sup>11</sup>, Reid F. Thompson<sup>5</sup>, Masako Suzuki<sup>5</sup>, Stephen Meltzer<sup>2</sup>, Ari Melnick, John M. Greally<sup>9</sup>, Anirban Maitra<sup>1,3,4</sup>, Amit Verma<sup>5</sup>. PLoS Genet. 2011 Mar;7(3):e1001356. Epub 2011 Mar 31. Erratum in: PLoS Genet. 2011 May;7(5). **ISI 9.5**
4. HYALINIZING CHOLECYSTITIS AND ASSOCIATED CARCINOMAS: CLINICOPATHOLOGIC ANALYSIS OF A DISTINCTIVE VARIANT OF CHOLECYSTITIS WITH PORCELAIN-LIKE FEATURES AND ACCOMPANYING DIAGNOSTICALLY CHALLENGING CARCINOMAS. Samip Patel<sup>1</sup>, Juan Carlos Roa<sup>2</sup>, Oscar Tapia<sup>2</sup>, Nevra Dursun<sup>3</sup>, Olca Basturk<sup>4</sup>, Asli Cakir<sup>1</sup>, Hector Losada<sup>5</sup>, Juan Sarmiento<sup>6</sup>, N. Volkan Adsay<sup>1</sup> Am J Surg Pathol. 2011 Aug;35(8):1104-13 **ISI 4,1**
5. HPV DETECTION AND GENOTYPING IN PRENEOPLASTIC AND NEOPLASTIC LESIONS OF CERVIX UTERINE.. Jaime López M.<sup>1</sup>, Carmen Gloria Ili G.<sup>1</sup>, Priscilla Brebi M.<sup>1</sup>, Patricia García M.<sup>1</sup>, Pamela Leal R.<sup>1</sup>, Marcelo Garcés C.<sup>1</sup>, Italo Capurro V.<sup>3</sup>, Pablo Guzmán G.<sup>1,2</sup>, José Manuel Ojeda F.<sup>4</sup>, Eugenio Suárez P.<sup>5</sup> y Juan Carlos Roa S.<sup>1,2</sup> Rev.

*méd. Chile*, Nov 2010, vol.138, no.11, p.1343-1350. ISSN 0034-9887. **ISI 0.37**

6. HIDATIDOSIS DE LA MAMA: REPORTE DE UN CASO Y REVISIÓN DE LA LITERATURA Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S. *Rev Chil Cir*, Oct 2010, vol.62, no.5, p.516-519. ISSN 0718-4026 **ISI 0,2**
7. GLEASON SCORE IN PROSTATE CANCER. CORRELATION BETWEEN CORE BIOPSY AND RADICAL PROSTATECTOMY. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S *Rev Med Chil*. 2011 Feb;139(2):171-6. Epub 2011 Jul 11 **ISI 0.37**
8. GALLBLADDER CARCINOSARCOMA: A CASE REPORT AND REVIEW OF LITERATURA. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S *Rev Chil Cir*, Feb 2011, vol.63, no.1, p.76-80. ISSN 0718-4026. **ISI 0.2**
9. MORPHOLOGICAL PROGNOSTIC FACTORS IN GASTRIC CANCER PATIENTS Juan Carlos Roa S<sup>1</sup>, Oscar Tapia E<sup>1</sup>, Carlos Manterola D<sup>2, 3</sup>, Miguel Villaseca H<sup>1</sup>, Juan Carlos Araya O<sup>1</sup>, Pablo Guzmán G<sup>1</sup> *Rev Chil Cir*, Abr 2011, vol.63, no.2, p.154-161. ISSN 0718-4026 **ISI 0.2**
10. MORPHOLOGICAL PROGNOSTIC FACTORS IN EARLY GASTRIC CANCER. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S *Rev Chil Cir*, Abr 2011, vol.63, no.2, p.162-169. ISSN 0718-4026 **ISI 0.2**
11. MORPHOLOGICAL AND CLINICAL PROGNOSTIC FACTORS OF GASTRIC CANCER WITHOUT LYMPHATIC INVOLMENT (pN0):. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa *Rev Med Chil*. 2011 Apr;139(4):432-8. Epub 2011 Aug 25 **ISI 0.37**
12. CANCER DE LA VESICULA BILIAR: ESTUDIOS NECESARIOS PARA EL DISEÑO DE ESTRATEGIAS DE PREVENCIÓN Y DIAGNOSTICO PRECOZ. Juan Carlos Roa S, Catterina Ferreccio, Juan Francisco Miquel. *Revista Medica Clínica Las Condes* 2011;22(4)486-91. **NO ISI**

## **Año 2010**

1. THE AXL RECEPTOR TYROSINE KINASE REGULATES THE RAL GTPASE PATHWAY AND ACTIVATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY *Translational Implications for Disease Progression and Therapeutic Resistance in Barrett-associated Esophageal Adenocarcinoma* Alvarez H, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu J, Heckrodt TJ, Zhang J, Ding P, Goff D, Singh R, Roa JC,

Marimuthu A, Riggins GJ, Eshleman JR, Nelkin BD, Pandey A, Maitra A. *Cancer Biol Ther.* 2010 Nov 4;10(10). **ISI 2.9**

2. CANCER OF COLON AND RECTUM: MORPHOLOGICAL AND CLINICAL DESCRIPTION OF 322 CASES. Oscar Tapia E, Juan Carlos Roa S, Carlos Manterola D, Enrique Bellolio J. *Int. J. Morphol.*, 28(1):2010. **ISI 0.36**
3. HIDATIDOSIS DE LA MAMA: REPORTE DE UN CASO Y REVISIÓN DE LA LITERATURA. Oscar Tapia E, Viviana Pineda N, Juan Carlos Roa S. *Aceptado Rev. Chilena de Cirugía.* Vol 62 - N° 5, 2010. **ISI 0.2**
4. HUMAN PAPILOMAVIRUS GENOTYPING IN CERVICAL ADENOCARCINOMA IN THE REGION OF LA ARAUCANIA-CHILE. Angélica Melo A., Patricia García M., Italo Capurro V., Pablo Guzmán G. y Juan Carlos Roa *Rev Chil Infectol* 2010;(4):297-301 **ISI 0.36**
5. DUODENAL VILLOUS ATROPHY ASSOCIATED WITH MYCOPHENOLATE MOFETIL: REPORT OF ONE CASE. Oscar Tapia E, Miguel Villaseca H, Armando Sierralta Z, Juan Carlos Roa S. [Rev Med Chil.](#) 2010 May;138(5):590-4 **ISI 0.37**
6. GASTRIC CANCER IN CHILE. CLINICAL AND MORPHOLOGICAL VARIABLES IN A TWO PERIODS COHORT (1986-1995 VS. 1996-2005) ESTUDIO DE COHORTE. Oscar Tapia E, Juan Carlos Roa S, Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G. *Rev. Chil de Cir.* Vol 62 - N° 2, Abril 2010; pág. 125-130 **ISI 0.2**
7. MORPHOLOGICAL PROGNOSTIC FACTORS IN MALIGNANT MELANOMA OF SKIN A 13 YEARS FOLLOW UP PERIOD. Enrique Bellolio J, Alvaro San Martín L, Luis Quiñiñir S, Juan Orellana C, Oscar Tapia E, Patricio Rifo, Juan Carlos Roa S, Miguel Villaseca H. *Rev Chil Cir.* Vol 62 - N° 3, June 2010. **ISI 0.2**
8. MORPHOLOGICAL AND CLINICAL PROGNOSTIC FACTORS OF APENNDIX CARCINOMAS. A COHORT STUDY. Oscar Tapia E, Carlos Manterola D, Miguel Villaseca H, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S. *Rev Chil Cir.* Vol 62 - N° 3, June 2010 **ISI 0.2**
9. HIDATIDOSIS ÓSEA: REPORTE DE 5 CASOS Y REVISIÓN DE LA LITERATURA. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S *Enviado Revista Médica de Chile.* *Rev. méd. Chile*, Nov 2010, vol.138, no.11, p.1414-1421 **ISI 0.37**
10. PRIMARY CUTANEOUS MUCORMYCOSIS A two cases report study and literature review. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D,

Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S Submitted to Rev med Chil (June 2/2010) **ISI 0.37**

11. HALLAZGOS MORFOLÓGICOS EN CASOS FATALES DE SÍNDROME CARDIOPULMONAR POR HANTAVIRUS. ESTUDIO DE 7 AUTOPSIAS Pablo Guzmán G., Oscar Tapia E., Miguel Villaseca H., Juan Araya O., Lilia Antonio P., Bolívar Lee O. y Juan Roa S. Rev Chil Infect 2010; 27 (5): 398-405. **ISI 0.36**
12. BELLOLIO J ENRIQUE, SAN MARTÍN L ALVARO, QUIÑIÑIR S LUIS, ORELLANA C JUAN, TAPIA E OSCAR, RIFO L PATRICIO et al . Evaluación de factores histológicos pronósticos de sobrevida en melanoma maligno cutáneo, seguimiento de 13 años. Rev Chil Cir [revista en Internet]. 2010 Ago [citado 2011 Abr 12] ; 62(4): 331-338 **ISI 0.2**
13. SURVIVAL OF A COHORT OF PATIENTS WITH INTERMEDIATE AND ADVANCED GALL BLADDER CANCER TREATED WITH A PROSPECTIVE THERAPEUTIC PROTOCOL. Manterola C, Vial M, Roa JC. Acta Cir Bras 2010;25:225-230. **ISI 0.5**
14. GASTRIC SIGNET CELL CARCINOMA: A PROGNOSTIC AND MORPHOLOGICAL COMPARISON WITH OTHER HISTOLOGICAL TYPES. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S. Rev Chil Cir, Oct 2010, vol.62, no.5, p.458-464. ISSN 0718-402 **ISI 0.2**
15. GALLBLADDER CARCINOSARCOMA : A CASE REPORT AND REVIEW OF LITERATURA.. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S Submitted to Rev Cir Chil (april 23th/2010). **ISI 0.2**
16. PRIMARY CUTANEOUS MUCORMICOSIS A two cases report study and literature review. Oscar Tapia E Miguel Villaseca H, Carlos Manterola D, Plácido Flores, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S Submitted to Rev med Chil (June 2/2010) **ISI 0.37**
17. MORPHOLOGICAL AND CLINICAL PROGNOSTIC FACTORS OF APENNDIX CARCINOMAS. A COHORT STUDY. Oscar Tapia E, Carlos Manterola D, Miguel Villaseca H, Juan Carlos Araya O, Pablo Guzmán G, Juan Carlos Roa S. Rev Chil Cir. Vol 62 - N° 3, June 2010 **ISI 0.2**

#### **5. Libros y patentes: (últimos 10 años)**

1.-MOLECULAR PATHOLOGY OF LIVER DISEASES, P Monga, ed Ch. 63: "Molecular Pathology of Neoplasms of Extrahepatic Bile Ducts" Nora Katabi, Juan Carlos Roa, and N. Volkan Adsay Springer 2011 Hardcover, ISBN 978-1-4419-7106-7 pages 881-890

2.-MOLECULAR PATHOLOGY OF LIVER DISEASES, P Monga, ed

Ch. 64: "Neoplasms of the Gallbladder" Juan Carlos Roa, Nora Katabi, and Volkan Adsay. Springer New York Hardcover, ISBN 978-1-4419-7106-7. Pages 891-905

3.-.- New Research on Precancerous Conditions. Editors: Jennifer E. Litchfield. PRENEOPLASTIC LESIONS OF A GALLBLADDER FROM MORPHOLOGICAL AND MOLECULAR POINTS OF VIEW. Juan Carlos Roa MD. Iván Roa MD. Nova editorial 2007 US New York ISBN: 1-60021-552-1

4.-.- Tumor Markers Research Focus. Editors: Deborah H. Chang SPECIFIC GENE METHYLATION AS A GASTROINTESTINAL TUMOR MARKER. Juan Carlos Roa<sup>1</sup>, Miguel Villaseca<sup>1</sup> Nova editorial 2007 US New York ISBN: 1-60021-544-0

5.-.- DNA Methylation Research TRENES. Editors: Taku B. Kobayashi METHYLATION IN CANCER RESEARCH Juan Carlos Roa S. and Patricia García M. Nova editorial 2007 US New York ISBN: 1-60021-721-4

6.-.- Research Focus on Gastric Cancer Editors: Dorothy C. Cardini FUTURE DIRECTIONS IN GASTRIC CANCER RESEARCH Juan Carlos Roa S. and Pamela Leal . Nova editorial 2008 ISBN: 1-60021-726-5 US New York

7.-.- CIRUGIA PANCREATICA Roa J. Capitulo de biología molecular del cancer de Páncreas. Sociedad de Cirujanos de Chile. ISBN 956-291-536-0. pag 163-171 CHILE 2002.

8.-.- CIRUGIA DEL HIGADO VIA BILIAR Y PANCREAS Consideraciones generales y genetico-moleculares del cáncer de los conductos biliares y de la vesícula biliar. Sociedad de Cirujanos de Chile. ISBN 956-7416-04-4. pag 38-56 2005. CHILE.

9.-.- NOSE AND VIRAL CANCER: ETIOLOGY, PATHOGENESIS AND TREATMENT EDITORS: Aloisio Medeiros and Carlitos Veloso "VIRAL CANCERS: ETIOLOGY, PATHOGENESIS, AND TREATMENT." Priscilla Brebi Carmen Gloria Illi Jaime Lopez Juan Carlos Roa Nova editorial 2009 US New York ISBN: 978-1-60741-735-4.

10.- MOLECULAR GENETIC ALTERATIONS IN PRENEOPLASTIC AND NEOPLASTIC LESIONS OF THE GALLBLADDER IN "FIELD CANCERIZATION: BASIC SCIENCE AND CLINICAL APPLICATIONS". Juan Carlos Roa<sup>1</sup> and Jonathan Castillo<sup>2</sup> Nova editorial 2011 US New York ISBN 978-1-61761-006-6 pages 241-275

11.-. MOLECULAR GENETICS OF GALLBLADDER CANCER in "molecular pathology of organ systems for pathologists" Roa J. Adsay V. Springer In press 2012.



12.- MOLECULAR GENETICS OF GALLBLADDER CANCER.In: eLS. Espinoza, Jaime A; García, Patricia; Bizama, Carolina; and Roa, Juan C John Wiley & Sons, Ltd: Chichester. (March 2015)

### **Patentes**

- 1.-Novel Genes and uses thereof, expresion profile of colon, gastric and pancreatic 61/404,141 ( USA) 2011.
- 2.- Kit de deteccion y genotipificacion de HPV. "HPV easy typing"  
**NÚMERO DE TRAMITACIÓN 765-2015 ( INAPI) via PCT**